GB virus C viremia is associated with higher levels of double-negative T cells and lower T-cell activation in HIV-infected individuals receiving antiretroviral therapy

Journal of Infectious Diseases

Volumn 206, Issue 9, 2012, Pages 1469-1472

  Bhattarai, Nirjal ^a,b   Rydze, Robert T ^a,b,c   Chivero, Ernest T ^a,b   Stapleton, Jack T ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD38 ANTIGEN; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOUBLE NEGATIVE T LYMPHOCYTE; FEMALE; HEPATITIS G; HEPATITIS G VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GB VIRUS C; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIREMIA;

EID: 84867562525     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis515     Document Type: Article

References (15)

1. Mohr EL, Stapleton JT. GB virus type C interactions with HIV: The role of envelope glycoproteins. J Viral Hepat 2009; 16:757-68.
2. Zhang W, Chaloner K, Tillmann HL, Williams CF, Stapleton JT. Effect of early and late GB virus C viraemia on survival of HIVinfected individuals: A meta-analysis. HIV Med 2006; 7:173-80. (Pubitemid 43337596)
3. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715-24.
4. Bhattarai N, Stapleton JT. GB virus C: The good boy virus? Trends Microbiol 2012; 20:124-30.
5. George SL, Varmaz D, Stapleton JT. GB virus C replicates in primary T and B lymphocytes. J Infect Dis 2006; 193:451-4. (Pubitemid 43122346)
6. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008; 22:439-46. (Pubitemid 351317285)
7. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 2006; 12:289-95. (Pubitemid 43355074)
8. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-8. (Pubitemid 37070273)
9. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33. (Pubitemid 351263476)
10. Rydze RT, Bhattarai N, Stapleton JT. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T cell death. Antivir Ther 2012; in Press.
11. Stapleton JT, Chaloner K, Zhang J, et al. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS 2009; 23:605-10.
12. Maidana-Giret MT, Silva TM, Sauer MM, et al. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 2009; 23:2277-87.
13. D'Acquisto F, Crompton T. CD37 + CD4-CD8-(double negative) T cells: Saviours or villains of the immune response? Biochem Pharmacol 2011; 82:333-40.
14. Petitjean G, Chevalier MF, Tibaoui F, et al. Level of double negative T cells, which produce TGF-beta and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. AIDS 2012; 26:139-48.
15. Voelkl S, Gary R, Mackensen A. Characterization of the immunoregulatory function of human TCR-alphabeta+ CD4-CD8-doublenegative T cells. Eur J Immunol 2011; 41:739-48.